The current standard of care for asthma leaves large numbers of sufferers at risk for severe exacerbations and even death. But emerging targeted therapies that may provide better treatment options also face obstacles. Sarah Webb reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Corren, J. et al. N. Engl. J. Med. published online, doi:10.1056/NEJMoa1106469 (3 August 2011).
Mullane, K. Biochem. Pharmacol. 82, 567–585 (2011).
Moore, W.C. Am. J. Respir. Crit. Care Med. 181, 315–323 (2010).
Woodruff, P.G. et al. Proc. Natl. Acad. Sci. USA 104, 15858–15863 (2007).
Jia, G.-Q. et al. Am. J. Respir. Crit. Care Med. 183, A4455 (2011).
Barnes, P.J. Nat. Rev. Immunol. 8, 183–192 (2008).
Krieg, A.M. Nat. Med. 9, 831–835 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Webb, S. Attacks on asthma. Nat Biotechnol 29, 860–863 (2011). https://doi.org/10.1038/nbt.1994
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1994
